medigraphic.com
ISSN 0016-3813 (Impreso)

2007, Número 1

<< Anterior Siguiente >>

Gac Med Mex 2007; 143 (1)


II. Preparación de nuevas fenilamidas anticonvulsionantes

Meza-Toledo SE, Carvajal-Sandoval G

Idioma: Español
Referencias bibliográficas: 31
Paginas: 34-38
Archivo PDF: 103.14 Kb.


RESUMEN

En el presente trabajo se prepararon una serie nueva de fenilamidas anticonvulsionantes conteniendo los grupos trifluorometilo, flúor, bromo y cloro en el anillo aromático de los compuestos DL-2- hidroxi-2-etil-2-fenil acetamida (DL-HEPA), DL-3-hidroxi-3-etil- 3-fenilpropionamida (DL-HEPP) y DL-4-hidroxi-4-etil-4-fenilbutiramida (DL-HEPB). Los compuestos preparados presentaron una actividad anticonvulsionante bastante significativa contra las convulsiones y la muerte provocadas por el metrazol en ratones. La incorporación de halógenos en el anillo aromático de DL-HEPA, DL-HEPP y DL-HEPB condujo a compuestos con una actividad anticonvulsionante similar a la del fenobarbital. Se presentan evidencias de que las fenilamidas preparadas podrían actuar como antagonistas de los receptores del GABA.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Kohllng R. GABA becomes exciting. Science 2002;298:1350-1351.

  2. Dichter MA. Emerging insights into mechanisms of epilepsy: implications for new antiepileptic drug development. Epilepsia 1994;35:S51-S57.

  3. Martínez-Muñoz D, Meza-ToIedo SE. Acciones bioquímicas de los compuestos antiepilépticos. En: Farmacología Clínica. Víctor Uriarte-Bonilla V, Trejo-Caso SS (Eds.) Trillas, 1a. Edición, México D.F., México, 2003, pp 799-806.

  4. Cohen I, Navarro V, Clemenceau S, Baulae M, Miles R. On the origin of interictal activity in human temporal lobe epilepsy in vitro. Science 2002;298:1418-1421.

  5. Fukuda A. Diuretic soothes seizures in newborns. Nature Med 2005;11:1153-1154.

  6. Dzhala VI, Talos DM, Sdrulla DA, Brumbaek AC, Mathews GC, Benke TA, et al. NKCC1 transporter facilitates seizures in the developing brain. Nature Med 2005;11:1205-1213.

  7. Vergnes M, Mareseaux C, Micheletti G, Depaulis A, Rumbaeh L, Warker JM. Enhancement of spike and wave discharges by GABAmimetic drugs in rats with spontaneous petit mal like seizures. Neurosci Lett 1984;44:91-94.

  8. Gloor P, Fariello RG. Generalized epilepsy: some of its cellular mechanisms differ from those of focal epilepsy. Trends Neurosci 1988;11:63-68.

  9. Snead OC. The ontogeny of GABAergic enhancement of the γ -hydroxybutyrate model of generalizad absence seizures. Epilepsia 1990;31:363-368.

  10. Liu Z, Vergnes M, Depaulis A, Marescaux C. Involvement of intrathalamic GABAB neurotransmission in the control of absence seizures in the rat. Neurosci 1992;48:87-93.

  11. Marescaux C, Liu Z. Bemaseoni R, Vergnes M. GABAB receptors are involved in the occurrence of absence seizures in rats. Pharmacol Commun 1992;2:57-62.

  12. Hosford DA, Wang Y, Che-Liu C, Snead OC. Characterization of the antiabsence effects of SCH50911, a GABAB receptor antagonist, in the lethargic mouse, γ -hydroxybutyrate, and pentylenetetrazole models. J Pharrn Exp Ther 1995;274:1399-1403.

  13. Guerrini R, Belmonte A, Genton P. Antiepileptic drug-induced worsening of seizures in children. Epilepsia 1998;39:52-510.

  14. Meza-Toledo SE, Zenteno-García MT, Juárez-Carvajal E, Martínez-Muñoz D, Carvajal-Sandoval G. A new Homologous series of anticonvulsants: phenyl alcohol amides. Synthesis and pharmacological evaluation. Arzneim Forsch/Drug Res 1990;40(II):1289-1291.

  15. Pérez-de la Mora M, Tapia R. Anticonvulsant effect of 5-ethyl, 5-phenyl, 2-pyrrolidinone and its possible relationship to γ -aminobutyric acid-dependent inhibitory mechanisms. Biochem PharmacoI 1973;2635-2639.

  16. Solis H, Jurado JL. Femández-Guardiola A. La acción de la butiramida sobre el desarrollo del “Kindling” y el “Kindling amigdalino” ya establecido en el gato. En: Neurobiología, Simposium Internacional. Velasco-Suárez MM, Escobedo-Ríos F (Eds.) Progreso, México D.F., México, 1979, pp 83-94.

  17. Brailowsky S, Montiel T, Hernández E, Marescaux C, Vergnes M. Effects of 3-hydroxy, 3-ethyl, 3-phenylpropionamide (HEPP) on rat models of generalized and focal epilepsy. Epilepsy Res 1992;11:167-172.

  18. Meza-Toledo SE, Juárez-Carvajal E, Carvajal-Sandoval G. Synthesis of a new homologous series of p-chlorophenyl alcohol amides, their anticonvulsant activity and their testing as potential GABAB receptor antagonists. Arzneim Forsch/Drug Res 1998;48:797-801.

  19. Hill DR, Bowery NG. 3H-baclofen and 3H-GABA bind to bicucullineinsensitive GABAB sites in ret brain. Nature 1981;290:149-152.

  20. Kerr DIB, Ong J. GABA agonists and antagonists. Med Res Rev 1992;12:593-636.

  21. Carvajal-Sandoval G, Juarez-Carvajal E, Cruz-Peinado C, Meza-Toledo SE. Synthesis and pharmacological evaluation of a new homologous series of (±)-p-fluoro-phenyl alcohol amide anticonvulsants. Arzneim Forsch/Drug Res 1998;48:349-352.

  22. Meza Toledo SE, Ortega-González C, Juárez-Carvajal E, Carvajal-Sandoval G. Stereoselective anticonvulsant activity of the enantiomers of (±)-2-hydroxy-2-phenylbutyramide. Arzneim Forsch/Drug Res 1995;45:756-759.

  23. Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther 1949;96:99-113.

  24. Meza Toledo SE, Bowery NG. Baclofen inhibits electrically evoked GABA release from rat substantia nigra slices without evidence for autoreceptors. Br J Pharmacol 2000;131:46p.

  25. Tapia R, Drucker-Colín RR, Meza-Ruiz G, Durán L, Levi G. Neurophysiological and neurochemical studies on the action of the anticonvulsant γ -hydroxy, γ -ethyl, γ -phenylbutyramide. Epilepsia 1979:20:135-145.

  26. Iadarola MJ, Gale K. Substantia nigra: site of anticonvulsant activity mediated by gamma-amlnobutyric acid. Science 1982;218:1237-1240.

  27. Arbilla S, Kamal L, Langer SZ. Presynaptic GABA autoreceptors on GABAergic nerve endings of the rat substantia nigra. Eur J PharmacoI 1979;57:211-217.

  28. Floran B, Silva I, Nava C, Aceves J. Presynaptic modulation of the release of GABA by GABAA receptors in pars compacta and by GABAB receptors in pars reticulata of the substantia nigra. Eur J PharmacoI 1988;150:277-286.

  29. Bowery NG. GABAB receptor pharmacology. Annu Rev Pharmacol ToxicoI 1993;33:109-147.

  30. Chebib M, Hanrahan JR, Mewett KN, Duke RK, Johnston GAR. lonotropic GABA receptors as therapeutic targets for memory and sleep disorders. Ann Rep Med Chem 2004;39:13-23.

  31. Froesti W, Mickel SJ, Von-Sprecher O, Diel PJ, Hall RG, Maier L, et al. Phosphinic acid analogues of GABA. 2. Selective, orally active GABAB antagonists. J Med Chem 1995;38:3313-3331.




2020     |     www.medigraphic.com